Filtered By:
Source: The American Journal of Cardiology
This page shows you your search results in order of date. This is page number 20.
Order by Relevance | Date
Total 715 results found since Jan 2013.
Extended Cardiac Monitoring in Patients with Severe Sleep Apnea and no History of Atrial Fibrillation (The Reveal XT-SA Study)
Atrial fibrillation (AF) is a risk factor for ischemic stroke and reported to be associated with severe obstructive sleep apnea (OSA). The aim of this study was to determine the occurrence of newly detected AF in patients with severe OSA and no prior history of AF. Prospective observational study included patients with severe OSA (Apnea-Hypopnea Index (AHI) ≥ 30) and no history of AF. Primary outcome was detection of AF lasting ≥10 s. Patients were subjected to 2 24-hour Holter monitors, and if no AF was detected, implanted with a Medtronic Reveal XT implantable loop recorder (ILR).
Source: The American Journal of Cardiology - September 7, 2018 Category: Cardiology Authors: Cynthia Yeung, Doran Drew, Sharlene Hammond, Wilma M. Hopman, Damian Redfearn, Christopher Simpson, Hoshiar Abdollah, Adrian Baranchuk Source Type: research
Relation of Anterior Cruciate Ligament Tears to Potential Chronic Cardiovascular diseases
We have enrolled a cohort of former National Football League players (n = 3,506) who played since 1960 to assess potential long term health consequences associated with participating in the sport. Each participant has completed a self-administered questionnaire including reporting of physician-diagnosed health conditions. One of the early assessments was to evaluate whether anterior cruciate ligament (ACL) tears were associated with later life co-morbidities, including cardiovascular effects. We used Cox proportional hazards to estimate hazard ratios (HR) for joint replacement surgeries, myocardial infarction, sleep apnea,...
Source: The American Journal of Cardiology - September 7, 2018 Category: Cardiology Authors: William P. Meehan, Marc G. Weisskopf, Supriya Krishnan, Caitlin McCracken, Ross Zafonte, Herman A. Taylor, Aaron Baggish, Alvaro Pascual-Leone, Lee M. Nadler, Frank E. Speizer Source Type: research
Lifetime Pattern of Atrial Fibrillation and the Risks of Stroke and Death in a Population-based Cohort of Men (From The Manitoba Follow-Up Study)
Atrial Fibrillation (AF) is associated with stroke and mortality. The arrhythmia can be sustained or intermittent. Prior studies that have used fixed covariates and short time horizons to examine the relationship between the pattern of AF and the occurrence of events have produced conflicting results. The Manitoba Follow-Up Study includes 3983 originally healthy men who have been followed with routine examinations since 1948. AF status during each visit was classified into the following patterns: free of AF, newly-diagnosed; intermittent AF – in sinus; intermittent AF – in AF; sustained AF.
Source: The American Journal of Cardiology - August 20, 2018 Category: Cardiology Authors: William F. McIntyre, Philip D. St John, Mahmoud Torabi, Robert B. Tate Source Type: research
Embolic and Other Adverse Outcomes in Symptomatic Versus Asymptomatic Patients with Atrial Fibrillation (from the ORBIT-AF Registry)
We examined the incidence of major adverse outcomes in patients with asymptomatic versus symptomatic AF using ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation), a nationwide US registry of AF patients. We compared stroke/non-CNS embolism, MACNE (Major Adverse Cardiovascular and Neurologic Events), bleeding, and death in 9,319 asymptomatic (defined by European Heart Rhythm Association (EHRA) score =1 or “no symptoms”) versus symptomatic patients.
Source: The American Journal of Cardiology - August 20, 2018 Category: Cardiology Authors: Munveer Thind, DaJuanicia N. Holmes, Marwan Badri, Karen S. Pieper, Amitoj Singh, Rosalia G. Blanco, Benjamin A. Steinberg, Gregg C. Fonarow, Bernard J. Gersh, Kenneth W. Mahaffey, Eric D. Peterson, James A. Reiffel, Jonathan P. Piccini, Peter R. Kowey, O Tags: Full Length Article Source Type: research
Dual Antiplatelet Therapy Cessation and Adverse Events after Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis. (From the PARIS Registry)
The impact of Dual Antiplatelet Therapy (DAPT) cessation after percutaneous coronary intervention with drug eluting stent implantation in patients at high atherothrombotic risk (ATR) remains unclear. We aimed to characterize the risk for adverse events, and its relationship with the mode of DAPT cessation in patients at atherothrombotic risk (HATR). Considering patients treated with drug-eluting stents among those enrolled in the PARIS registry, we defined subjects with prior myocardial infarction (MI), prior stroke or peripheral vascular disease at HATR, while patients without any of these conditions were classified as at...
Source: The American Journal of Cardiology - August 20, 2018 Category: Cardiology Authors: Sabato Sorrentino, Gennaro Giustino, Usman Baber, Samantha Sartori, David J. Cohen, Timothy D. Henry, Serdar Farhan, Madhav Sharma, Cono Ariti, George Dangas, Michael Gibson, Michela Faggioni, Mitchell W. Krucoff, Melissa Aquino, Jaya Chandrasekhar, David Source Type: research
Usefulness and Safety of Rivaroxaban in Patients Following Isolated Mitral Valve Replacement With A Mechanical Prosthesis
Rivaroxaban has previously been tested in experimental and animal models with encouraging results. We prospectively selected 7 patients between May 2017 and January 2018 who underwent isolated mitral valve replacement with a mechanic prosthesis and had unstable INR control at least 3 months after surgery. An intervention of rivaroxaban 15 mg was then administered twice daily for a period of 90 days. No patient presented intracardiac thrombus, reversible ischemic neurological deficit, ischemic or hemorrhagic stroke, hospitalization or death during 3 months of follow-up.
Source: The American Journal of Cardiology - July 15, 2018 Category: Cardiology Authors: Andr é R Durães, Yasmin de S L Bitar, Maria Luiza G Lima, Caroline C Santos, Igor S Schonhofen, José Admirço L Filho, Leonardo Roever Source Type: research
Meta-Analysis Comparing the Frequency of Stroke After Transcatheter Versus Surgical Aortic Valve Replacement
Stroke is one of the most feared complications of aortic valve replacement. Although the outcomes of transcatheter aortic valve implantation (TAVI) improved substantially over time, concerns remained about a potentially higher incidence of stroke with TAVI compared with surgical replacement (SAVR). However, comparative data are sparse. We performed a meta-analysis comparing the incidence of stroke among patients undergoing TAVI versus SAVR. Of the 5067 studies screened, 28 eligible studies (22 propensity-score matched studies and 6 randomized trials) were analyzed.
Source: The American Journal of Cardiology - July 5, 2018 Category: Cardiology Authors: Kuldeep Shah, Zakeih Chaker, Tatiana Busu, Vinay Badhwar, Fahad Alqahtani, Muhammad Alvi, Amelia Adcock, Mohamad Alkhouli Source Type: research
Meta-Analysis Comparing The Frequency of Stroke After Transcatheter vs. Surgical Aortic Valve Replacement
Stroke is one of the most feared complication of aortic valve replacement. Although the outcomes of transcatheter aortic valve implantation (TAVI) improved substantially overtime, concerns remained about a potentially higher incidence of stroke with TAVI compared with surgical replacement (SAVR). However, comparative data are sparse. We performed a meta-analysis comparing the incidence of stroke amongst patients undergoing TAVI versus SAVR. Of the 5067 studies screened, 28 eligible studies (22 propensity-score matched studies and 6 randomized trials) were analyzed.
Source: The American Journal of Cardiology - July 5, 2018 Category: Cardiology Authors: Kuldeep Shah, Zakeih Chaker, Tatiana Busu, Vinay Badhwar, Fahad Alqahtani, Muhammad Alvi, Amelia Adcock, Mohamad Alkhouli Source Type: research
Changes in Left Atrial Function after Transcutaneous Mitral Valve Repair
Left atrial (LA) reverse remodeling occurs after transcatheter mitral valve repair, but additional data are needed about changes in LA function. Changes in LA stiffness in patients undergoing MitraClip were evaluated. Baseline, procedural and 30 day follow up clinical and imaging data of patients undergoing MitraClip were reviewed. LA operating chamber stiffness was calculated as ratio of systolic change in LA pressure to LA systolic strain and to stroke volume. Matched pre and post procedure LA strain analysis was performed in 35 patients, 21 with primary and 14 with functional MR.
Source: The American Journal of Cardiology - July 5, 2018 Category: Cardiology Authors: Eleonora Avenatti, Stephen H. Little, Colin M. Barker, Sherif F. Nagueh Source Type: research
Outcomes With Novel Oral Anticoagulants in Obese Patients who Underwent Electrical Cardioversion for Atrial Tachyarrhythmias
The efficacy of novel oral anticoagulants (NOACs) in severely obese patients is uncertain as volume of distribution is related to weight, and few such patients were enrolled in the pivotal trials. As the month after direct-current cardioversion (DCCV) for atrial fibrillation and atrial flutter is a high-risk period for stroke, we sought to evaluate the safety of performing DCCV in obese patients on NOAC. All patients who underwent DCCV after ≥3 weeks of NOAC or therapeutic warfarin treatment without a previous transesophageal echocardiogram over a 3-year period at a single center were included.
Source: The American Journal of Cardiology - July 4, 2018 Category: Cardiology Authors: Rachel M. Kaplan, Celso L. Diaz, Theresa Strzelczyk, Cindy You, Basil Saour, Michelle Fine, Amar Trivedi, Mark J. Shen, Prasongchai Sattayaprasert, Alexandru B. Chicos, Rishi Arora, Susan Kim, Albert Lin, Nishant Verma, Bradley P. Knight, Rod S. Passman Source Type: research
Outcomes with Novel Oral Anticoagulants in Obese Patients Undergoing Electrical Cardioversion for Atrial Tachyarrhythmias
The efficacy of novel oral anticoagulants (NOACs) in severely obese patients is uncertain as volume of distribution is related to weight and few such patients were enrolled in the pivotal trials. As the month following direct-current cardioversion (DCCV) for atrial fibrillation and atrial flutter (AF/AFL) is a high-risk period for stroke, we sought to evaluate the safety of performing DCCV in obese patients on NOAC. All patients who underwent DCCV after ≥ 3 weeks of NOAC or therapeutic warfarin treatment without a prior transesophageal echocardiogram (TEE) over a 3-year period at a single center were included.
Source: The American Journal of Cardiology - July 4, 2018 Category: Cardiology Authors: Rachel M. Kaplan, Celso L. Diaz, Theresa Strzelczyk, Cindy You, Basil Saour, Michelle Fine, Amar Trivedi, Mark J. Shen, Prasongchai Sattayaprasert, Alexandru B. Chicos, Rishi Arora, Susan Kim, Albert Lin, Nishant Verma, Bradley P. Knight, Rod S. Passman Source Type: research
Effect of Antiplatelet Therapy (Aspirin + Dipyridamole Versus Clopidogrel) on Mortality Outcome in Ischemic Stroke
The optimal regimen of antiplatelet therapy for secondary prevention in noncardioembolic ischemic stroke remains controversial. We aimed to determine which regimen was associated with the greatest reduction in adverse outcomes. We analysed prospectively collected data from the Norfolk and Norwich University Hospital Stroke Register. The sample population consisted of 3,572 participants (mean age 74.96 ± 12.67) with ischemic stroke, who were consecutively admitted between 2003 and 2015. Patients were placed on one of three antiplatelet regimens at hospital discharge; aspirin monotherapy, aspirin plus dipyridamole and clopidogrel.
Source: The American Journal of Cardiology - July 2, 2018 Category: Cardiology Authors: Raphae S. Barlas, Yoon K. Loke, Mamas A. Mamas, Joao H Bettencourt-Silva, Isobel Ford, Allan B. Clark, Kristian M. Bowles, Anthony K. Metcalf, John F. Potter, Phyo K. Myint Source Type: research
Effect of Antiplatelet Therapy (Aspirin + Dipyridamole vs Clopidogrel) on Mortality Outcome in Ischemic Stroke
The optimal regimen of antiplatelet therapy for secondary prevention in noncardioembolic ischemic stroke remains controversial. We aimed to determine which regimen was associated with the greatest reduction in adverse outcomes. We analysed prospectively collected data from the Norfolk and Norwich University Hospital Stroke Register (NNUHSR). The sample population consisted of 3,572 participants (mean age 74.96 ± 12.67) with ischemic stroke, who were consecutively admitted between 2003-2015. Patients were placed on one of three antiplatelet regimens at hospital discharge; aspirin monotherapy, aspirin plus dipyridamole and clopidogrel.
Source: The American Journal of Cardiology - July 2, 2018 Category: Cardiology Authors: Raphae S. Barlas, Yoon K. Loke, Mamas A. Mamas, Joao H Bettencourt-Silva, Isobel Ford, Allan B. Clark, Kristian M. Bowles, Anthony K. Metcalf, John F. Potter, Phyo K. Myint Source Type: research
Atrial fibrillation after percutaneous patent foramen ovale closure
We read with interest the recent article by Smer et al (1). In a meta-analysis of randomized trials, the authors reported the efficacy and safety of percutaneous patent foramen ovale (PFO) closure for prevention of recurrent stroke, in patients with an index cryptogenic stroke. Among 3440 patients included (five trials), the authors found that PFO closure decreases the risk of stroke compared with medical therapy (2.8% vs 5.8%; RR 0.48, CI 0.27-0.87, p=0.01) but increases risk of atrial fibrillation or flutter (AF) (4.2% vs 0.7%; RR 4.55, CI 2.16-9.6, p=0.0001).
Source: The American Journal of Cardiology - June 5, 2018 Category: Cardiology Authors: Mohammad K. Mojadidi, Akram Y. Elgendy, Islam Y. Elgendy, Ahmed N. Mahmoud, Bernhard Meier Source Type: research
Meta-analysis Comparing Catheter Guided Ablation Versus Conventional Medical Therapy for Patients with Atrial Fibrillation and Heart Failure with Reduced Ejection Fraction
The prognostic benefit of catheter ablation (CA) for atrial fibrillation (AF) in the setting of heart failure (HF) with reduced ejection fraction (EF) is unclear. A systematic search of medical literature was limited to randomized controlled trials. The primary outcome was all-cause mortality and secondary outcomes were HF hospitalizations, stroke, left ventricular EF improvement, change in 6-minute walk test ( Δ 6MWT) and change in Minnesota living with heart failure questionnaire (Δ MLHFQ). Random effects risk ratios (RR) were calculated for categorical outcomes and standardized mean differences (SMD) for continuous on...
Source: The American Journal of Cardiology - June 4, 2018 Category: Cardiology Authors: Akram Y. Elgendy, Ahmed N. Mahmoud, Muhammad S. Khan, Maryam R. Sheikh, Mohammad K. Mojadidi, Mohamed Omer, Islam Y. Elgendy, Anthony A. Bavry, Kenneth A. Ellenbogen, William M. Miles, Matthew McKillop Source Type: research
